Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Viridian Therapeutics (VRDN)
NASDAQ:VRDN
RESEARCH TOOLSreports
Viridian Therapeutics (VRDN) Stock Price & Analysis
1,022 Followers
VRDN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$10.93 - $25.05
Previous Close$13.21
Volume532.76K
Average Volume (3M)969.50K
Market Cap
$843.09M
Enterprise Value$341.88M
Total Cash (Recent Filing)$521.55M
Total Debt (Recent Filing)$20.33M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Aug 07, 2024EPS Estimate
-$0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.50
Shares Outstanding63,822,468
10 Day Avg. Volume1,427,105
30 Day Avg. Volume969,505
Standard Deviation0.42
R-Squared0.02
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)2.21
Price to Sales (P/S)11142.34
Price to Cash Flow (P/CF)-5.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.19K
Enterprise Value/Gross Profit1.09K
Enterprise Value/Ebitda-2.10
Forecast
1Y Price Target
$33.08Price Target Upside172.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Viridian Therapeutics News
PremiumCompany Announcements
Viridian Therapeutics’ Shareholders Approve Equity Plan Expansion
Bulls Say, Bears Say
Bulls Say
Clinical AdvantageFull inhibition of IGF-1R signaling by VRDN-001/003 could drive better efficacy compared to Tepezza.
Patient ConvenienceVRDN-003 looks to be a best-in-class IGF-1R inhibitor that can be dosed as a self-administered, low-volume SC injection.
Regulatory AlignmentThe company has finalized the design of their pivotal Phase 3 development program for VRDN-003 in thyroid eye disease, following positive discussions and alignment with FDA.
Bears Say
Clinical TrialsThe missing placebo data and unknown data variance complicate the visibility of clinical trial outcomes.
Market CompetitionWith competitor Amgen advancing their own subcutaneous Tepezza program, there is increased pressure on VRDN to execute effectively in a competitive market.
Regulatory DelaysConfirmation of an additional study pushed the BLA filing by six months.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VRDN FAQ
What was Viridian Therapeutics’s price range in the past 12 months?
Viridian Therapeutics lowest stock price was $10.93 and its highest was $25.05 in the past 12 months.
What is Viridian Therapeutics’s market cap?
Currently, no data Available
When is Viridian Therapeutics’s upcoming earnings report date?
Viridian Therapeutics’s upcoming earnings report date is Aug 07, 2024 which is in 35 days.
How were Viridian Therapeutics’s earnings last quarter?
Viridian Therapeutics released its earnings results on May 08, 2024. The company reported -$0.79 earnings per share for the quarter, beating the consensus estimate of -$1.089 by $0.299.
Is Viridian Therapeutics overvalued?
According to Wall Street analysts Viridian Therapeutics’s price is currently Undervalued.
Does Viridian Therapeutics pay dividends?
Viridian Therapeutics does not currently pay dividends.
What is Viridian Therapeutics’s EPS estimate?
Viridian Therapeutics’s EPS estimate is -$0.87.
How many shares outstanding does Viridian Therapeutics have?
Viridian Therapeutics has 63,822,468 shares outstanding.
What happened to Viridian Therapeutics’s price movement after its last earnings report?
Viridian Therapeutics reported an EPS of -$0.79 in its last earnings report, beating expectations of -$1.089. Following the earnings report the stock price went down -1.585%.
Which hedge fund is a major shareholder of Viridian Therapeutics?
Among the largest hedge funds holding Viridian Therapeutics’s share is Perceptive Advisors LLC. It holds Viridian Therapeutics’s shares valued at 64M.
---
Viridian Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.08 (172.04% Upside)
$33.08 (172.04% Upside)
Blogger Sentiment
Bullish
VRDN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 3.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 13.4%
Last 30 Days ▲ 13.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.47%
12-Months-Change
Fundamentals
Return on Equity
-46.75%
Trailing 12-Months
Asset Growth
63.04%
Trailing 12-Months
Company Description
Viridian Therapeutics
Miragen Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product pipelines include MRG-106 that focuses on the treatment of blood cancer; and MRG-201 deals with the treatment of pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.
---
VRDN Company Deck
---
VRDN Earnings Call
Q1 2024
0:00 / 0:00
---
VRDN Stock 12 Month Forecast
Average Price Target
$33.08
▲(172.04% Upside)
Technical Analysis
Best Analysts Covering VRDN
1 Year
1 Year Success Rate
11/31 ratings generated profit
1 Year Average Return
-9.46%
reiterated a buy rating 22 days ago
Copying Laura Chico's trades and holding each position for 1 Year would result in 35.48% of your transactions generating a profit, with an average return of -9.46% per trade.
---